🇺🇸 FDA
Patent

US 9084795

Compositions and methods for inhibition of the JAK pathway

granted A61KA61K31/155A61K31/506

Quick answer

US patent 9084795 (Compositions and methods for inhibition of the JAK pathway) held by Rigel Pharmaceuticals, Inc. expires Mon Jul 16 2035 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Rigel Pharmaceuticals, Inc.
Grant date
Tue Jul 21 2015 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jul 16 2035 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
19
CPC classes
A61K, A61K31/155, A61K31/506, A61K31/5377, A61K31/538